Once-weekly insulin icodec (Awiqli) for type 2 diabetes.

Abstract

Insulin icodec (Awiqli – Novo Nordisk), an ultra-long-acting basal human insulin analog, has been approved by the FDA for once-weekly treatment of type 2 diabetes. Two long-acting insulin analogs are available in the US for once-daily use: glargine and degludec (see Table 1). Insulin icodec has been available in Canada since 2024.